Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors

Noel D. D’Angelo(Amgen (United States)), Mark H. Norman(Amgen (United States)), Dan Freeman(Amgen (United States)), Raju Subramanian(Gilead Sciences (United States)), Michael Schrag(Amgen (United States)), Kevin Yang(Revolution Medicines (United States)), Jin Tang(Central South University), Leeanne Zalameda(Amgen (United States)), Tae‐Seong Kim(Korea Atomic Energy Research Institute), Derin C. D’Amico(Amgen (United States)), Tisha San Miguel(Amgen (United States)), Douglas A. Whittington(Amgen (United States)), Erin L. Mullady(Amgen (United States)), Jian Jiang(Xuzhou Medical College), Ning Xi(Zhongshan Hospital), Shon K. Booker(Amgen (United States)), Longbin Liu(National University of Defense Technology), Ling Wang(Guizhou University), Kui Chen(Sinopec (China)), Yang Xu(Amgen (United States)), Paul E. Hughes(Amgen (United States)), Nancy Zhang(Amgen (United States)), Tian Wu(Guangzhou University of Chinese Medicine), Sean Caenepeel(Amgen (United States)), Kristin L. Andrews(Amgen (United States)), John D. McCarter(Amgen (United States)), Robert C. Wahl, P. Yakowec(Amgen (United States))
Journal of Medicinal Chemistry
February 18, 2011
Cited by 120


Related Papers